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Previously, priming rhesus macaques with Adenovirus type 5 host range mutant-recombinants
encoding Tat and Env and boosting with Tat and Env protein in MPL-SE controlled chronic viremia
by 4 logs following homologous intravenous SHIV89.6P challenge. Here we evaluated Tat, Env, and
Tat/Env regimens for immunogenicity and protective efﬁcacy using clade C Env, alum adjuvant, and a
heterologous intrarectal SHIV1157ipd3N4 challenge. Despite induction of strong cellular and humoral
immunity, Tat/Env group T and B-cell memory responses were not signiﬁcantly enhanced over Tat- or
Env-only groups. Lack of viremia control post-challenge was attributed to lower avidity Env antibodies
and no anamnestic ADCC response or SHIV1157ipd3N4 neutralizing antibody development post-challenge.
Poor biologic activity of the Tat immunogen may have impaired Tat immunity. In the absence of
sterilizing immunity, strong anamnestic responses to heterologous virus can help control viremia. Both
antibody breadth and optimal adjuvanticity are needed to elicit high-quality antibody for protective
efﬁcacy.
Published by Elsevier Inc.Introduction
Despite the success of highly active antiretroviral therapy (HAART)
which can suppress HIV replication to undetectable levels and has
shown 96% efﬁcacy in preventing viral transmission (Cohen et al.,
2011), an effective vaccine is still needed to ﬁght the global HIV
pandemic. To date, the most effective vaccine has been live attenu-
ated virus (Koff et al., 2006), however, the possible reversion of the
virus in vivo to a pathogenic form (Hofmann-Lehmann et al., 2003)
has limited the use of this approach. Nevertheless, individually, all
HIV structural, accessory and regulatory proteins may prove useful in
vaccine design. Some studies have shown that co-administration of
several HIV immunogens can lead to inhibition of immune responses
against one or more of the co-administrated immunogens (Toapanta
et al., 2007), although other studies have shown positive modulatoryInc.
h, National Cancer Institute,
D804, Bethesda,
-Guroff).effects (Patterson et al., 2003). Overall, the selection and combination
of HIV immunogens is critical for a successful HIV vaccine.
HIV structural proteins represent the main components in most
HIV vaccines. Env, Gag and Pol elicit both cellular and humoral
immunity, although in vaccine design Gag and Pol are intended to
elicit mainly cellular immunity, while Env is included primarily to
elicit antibodies, the key correlate of most successful vaccines.
Accessory/regulatory proteins, such as Tat, Rev, and Nef, have also
been incorporated into vaccines, primarily in combination strategies.
Tat, in particular, has been a key vaccine target in numerous
approaches due to its early expression in the viral life cycle and its
indispensible contribution as a transactivator protein to viral infec-
tivity and pathogenesis. Tat-speciﬁc immune responses elicited by
prophylactic vaccines might therefore help prevent viral transmission
and/or replication. As a vaccine immunogen, Tat has been shown to
enhance cellular immune responses to co-administered antigens, and
to elicit anti-Tat antibody in the absence of adjuvant. Tat-speciﬁc
humoral and cellular immune responses have been associated with
disease control in HIV-infected people, and SIV Tat-speciﬁc cellular
immune responses have been associated with control of acute SIV
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been recently reviewed by Caputo, et al. (2009).
Previously we reported that strong protection, evidenced by a
4-log reduction in viremia in the chronic phase of infection, was
elicited by combined immunization with Adenovirus type 5 host
range mutant (Ad5hr)-recombinants expressing Tat and Env followed
by boosting with Tat protein in alum and Env protein in monopho-
sphoryl lipid A-stable emulsion (MPL-SE), using a homologous
SHIV89.6P challenge model. In contrast, immunization with an
Ad5hr-HIVtat prime/Tat protein boosting regimen conferred no
protection at all (Demberg et al., 2007). In comparison with a
multigenic regimen (incorporating Env, Gag, Nef and Tat immuno-
gens) which reduced chronic viremia only 3 logs, the better chronic
phase protection resulting from the Tat/Env regimen was associated
with higher binding titers to Tat and Env and better antibody-
dependent cellular cytotoxicity (ADCC) mediating antibodies
(Florese et al., 2009). This result is in agreement with several other
studies in non-human primate models of SIV and SHIV infection, in
which vaccine-elicited high avidity antibodies mediating ADCC as
well as antibody-dependent cell-mediated viral inhibition (ADCVI)
are correlated with partial protection and control of viremia (Gomez-
Roman et al., 2005; Hidajat et al., 2009; Xiao et al., 2010). Moreover, itFig. 1. Real time PCR evaluation of cytokine and chemokine responses after Ad pri
2 weeks after the ﬁrst Adenovirus prime (A) and 3 (B) and 8 (C) days after the second A
the ﬁrst (D) and second (E) Adenovirus immunizations. Results are shown as the fold up
standard error of the mean (sem) are shown.is believed that the 30% protection achieved in the recent clinical
vaccine trial in Thailand (RV144) (Rerks-Ngarm et al., 2009) was
conferred at least in part by ADCC- mediating antibodies. Ninety-nine
percent of vaccinees exhibited binding antibodies to gp120 and 2/3 of
them had detectable ADCC titers to gp120-coated target cells (Haynes
et al., 2011).
The design of our previous Tat/Env study lacked an envelope
only vaccine group, so we could not distinguish the contribution
to protective efﬁcacy of Env versus Tat. Moreover, the dual tropic
SHIV89.6P challenge was homologous to the immunogens. Here we
have addressed these issues, and report our ﬁndings from a study
comparing immunogenicity and protective efﬁcacy of a Tat plus
Env immunization regimen to Tat only and Env only regimens
followed by a heterologous R5 tropic SHIV1157ipd3N4 challenge.Results
Cytokines/chemokines induced by Ad-recombinant vaccination
To determine if Tat expressed by Ad5hr-HIVtat could poten-
tially modulate immune responses, we examined induction byming in PBMC and BAL. Induction of cytokine and chemokine responses in PBMC
denovirus immunization. Cytokine and chemokine responses in BAL 2 weeks after
-regulation in response relative to pre-immunization values. Mean responses7the
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tative of both innate and adaptive acute immune responses, in
PBMC and bronchoalveolar lavage (BAL) cells. In PBMC, 2 weeks
after the ﬁrst Ad immunization, only MIP-1a was consistently up-
regulated more than 2-fold in all groups including the control
group which received Ad empty vector (Fig. 1A). MIP-1b and IL-15
were not up-regulated in any group. Up-regulation of the remaining
cytokines/chemokines across the 4 groups was sporadic. Three
days following the second Ad immunization, only IFN-g and
MIP-1a were consistently up-regulated more than 2-fold in all
groups (Fig. 1B). By 8 days after the second Ad, only IFN-g
exhibited greater than 2-fold up-regulation in all but the controls
(Fig. 1C).
BAL cells were examined as representative of a mucosal
effector site. Two weeks after the ﬁrst Ad immunization (intra-
nasal) they showed cytokine/chemokine levels higher than those
observed in PBMC after the ﬁrst Ad prime (Fig. 1D). TNF-a, IL-10,
MIP-1a and IL-8 were consistently up-regulated more than 2-fold
in all 4 macaque groups, as were IFN-g and MIP-1b in all but the
controls. Rantes was only up-regulated in the Env immunization
group. As with the PBMC, signiﬁcant differences between responses
by the Ad-recombinants compared to the Ad empty vector were not
obtained.
Two weeks after the second Ad immunization (intratracheal)
we observed stronger responses in the lung compared to responses
following the ﬁrst Ad administration (Fig. 1E), likely reﬂecting
improved targeting of Ad-recombinants to the upper respiratory
tract. All cytokines/chemokines measured were up-regulated more
than 2-fold. Overall, data in both PBMC and BAL showed no evidence
of modulation of cytokine/chemokine responses by the inserted
genes in the Ad recombinants. Rather, results obtained were in
response to the vector itself.Fig. 2. Pre-challenge humoral immune responses. Geometric mean (A) Tat- and (
(C) Tat- and (D) Env-speciﬁc binding antibodies, respectively, in rectal secretions.Cellular responses
In the previous Tat/Env study, vaccine-elicited cellular
immune responses were not associated with the potent protec-
tion in the Tat/Env immunization group. Similarly, as summarized
here, cellular immunity was not signiﬁcantly enhanced in the
Tat/Env group as assessed by IFN-g ELISpot and CSFE-proliferation
assays (Suppl. Fig. 1A–D). Central memory (CM; CD28þ/CD95þ),
transitional effector memory (TEM; CD28þCD95þCCR7), and
effector memory (EM; CD28/CD95þ) T cell subsets in PBMC
were evaluated by intracellular cytokine staining following the
second protein boost. In general, CD4þ T cells secreted higher
levels of cytokines compared to CD8þ T cells (Suppl. Fig. 2A and B).
Most of the CM Env- and Tat-speciﬁc responses occurred in TEM
subpopulations (Suppl. Fig. 2C–F). Evaluation of polyfunctionality
of peripheral blood CM, TEM, and EM cells showed the levels of
both Env- and Tat-speciﬁc responses were greatest in the Tat/Env
group, although Tat responses were much lower in magnitude
and rarely detected among CD4þ and CD8þ TEM cells (Suppl.
Fig. 3A–F). CD4þ Env-speciﬁc triple positive cells were progres-
sively elevated in the Tat/Env group as the cells matured from CM
to TEM to EM (Suppl. Fig. 3G). Overall, however, enhanced levels
and polyfunctionality of CD4þ EM cells in the Tat/Env group did
not reach statistical signiﬁcance. In contrast to Env-speciﬁc CD4þ
memory cells, CD8þ memory cells in PBMC contained very few
triple positive cells, while Tat-speciﬁc polyfunctional cells were at
the background level among CD8þ EM and CM cells (data not
shown).
We also analyzed total memory (TM) cells in BAL for cytokine
secretion. Following the second protein boost, secretion of IFN-g
and TNF-a was greatest in both CD4þ and CD8þ populations of
Tat/Env-immunized macaques compared to the Env-only group.B) Env-(HIVCZM gp120)-speciﬁc binding antibody titers, respectively, are shown.
Fig. 3. Challenge outcome of the current (A) and previous (B) Tat/Env studies.
Viral loads following challenge with SHIV1157ipd3N4 (A) and SHIV89.6P (B) are
expressed as geometric means7sem. Data in panel B are taken from Demberg
et al., 2007.
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levels (Suppl. Fig. 4A). BAL Env-speciﬁc CD4þ TM cells in the
Tat/Env group exhibited a greater proportion of double and triple
positive cells compared to those in the Env group (Suppl. Fig. 4B
and D), although this did not reach statistical signiﬁcance. In BAL
CD8þ TM cells, both the Env and Tat/Env groups were composed
of mainly single-positive IFN-g-secreting cells (Suppl. Fig. 4C).
Systemic binding antibody
As previous protection in the Tat/Env group was associated
with humoral immune responses, here we carefully examined a
number of antibody parameters. Serum binding antibody titers
to Tat and Env proteins were ﬁrst assessed. As puriﬁed
SHIV1157ipd3N4 Env was not available, we used HIVCZM Env,
heterologous to both the challenge virus and the HIVTV-1 immu-
nogen, as well as HIVTV-1 gp140. Tat antibody titers were in
general low, moderately boosted after the ﬁrst protein immuni-
zation and minimally boosted after the second (Fig. 2A). Peak
titers did not differ between the Tat and Tat/Env groups. Good
induction of antibody responses to HIVCZM gp120 were observed
in both the Env only and Tat/Env groups after the second Ad-
recombinant prime at week 14 (Fig. 2B), matching the appearance
of ELISpot and CD4 proliferative responses at the same time point
(Suppl. Fig. 1) and showing the effectiveness of Ad-recombinant
priming. Anti-Env titers in both groups were further boosted by
the protein vaccinations. Responses in both groups peaked after
the second protein boost (week 38) with no signiﬁcant difference
in geometric mean titers of the Env (10910) and Tat/Env (16510)
groups. As expected both the Env and Tat/Env groups exhibited
higher geometric mean antibody titers (approximately 6-fold) to
the TV-1 gp140 compared to the CZM gp120 at the week 38 time
point: 74,700 for the Env only group and 105400 for the Tat/Env
group (data not shown). However, this difference was not statis-
tically signiﬁcant.
We also assessed binding titers of IgG and IgA antibodies in
rectal secretions to HIV Tat and HIVCZM gp120. Rectal IgG antibodies
to Tat were initially detected after the second Ad-recombinant
immunization only in the Tat/Env group and were boosted by the
protein immunizations (Fig. 2C). Titers in the Tat-only group
remained at control levels. Similarly, Env-speciﬁc rectal IgG anti-
bodies developed in the Tat/Env group (Fig. 2D), but were increased
in both the Env and Tat/Env groups to similar levels by the protein
boosts. Env- and Tat-speciﬁc IgA antibodies in rectal secretions
appeared sporadically. Geometric mean antibody titers remained
close to control levels across the entire immunization regimen (data
not shown).
Antibody dependent cellular cytotoxicity
ADCC activity was shown to be consistently higher in the
original Tat/Env group in comparison to a multigenic group
(Florese et al., 2009). We evaluated it here using HIVCZM gp120-
coated target cells. Two weeks after the second protein immuni-
zation, the geometric mean antibody titer mediating ADCC was
520 for the Env only group and 2680 for the Tat/Env group (data
not shown). As with the binding titers, this difference was not
statistically signiﬁcant.
Viral challenge
Fifty weeks after initial immunization, the macaques were
challenged intrarectally with SHIV1157ipd3N4. All animals became
infected (Fig. 3A). No differences in peak or chronic viremia were
observed between groups. The Tat/Env group showed somewhat
lower viral loads than the other 3 groups during the ﬁrst 10 weekspost-infection, but this trend did not reach signiﬁcance. Overall
there was no difference in CD4 T-cell counts between groups over
the post-challenge monitoring period. All but the Tat group
maintained approximately 52–83% of their initial CD4 T-cell
levels while the Tat group tended to show somewhat increased
numbers (data not shown). In keeping with the preservation of
CD4 T cells, none of the animals progressed to AIDS.
The results of the heterologous challenge conducted here
contrasted greatly with our previous Tat/Env study in which
macaques received a homologous SHIV89.6P challenge (Demberg
et al., 2007; Fig. 7B). In that ﬁrst study, the Tat only group
exhibited no reduction in chronic viremia, as seen here, while
the Tat/Env group exhibited a strong, signiﬁcant 4-log reduction
in chronic viremia. In subsequent experiments we attempted to
elucidate differences in vaccine-elicited immune responses that
led to the strikingly different challenge outcomes.
Role of memory cells
As both CD4 and CD8 memory T cells were elicited by the
current vaccine regimen, we initially assessed post-challenge Env
and Tat-speciﬁc responses in PBMC. No evidence of either a Tat-
or Env-speciﬁc cellular anamnestic response was observed
(Fig. 4). Responses against both antigens declined continually
from levels observed 4 weeks prior to challenge. The Env ELISpot
Fig. 4. Post-challenge ELISpot responses. Mean (A) Tat- and (B) Env-(HIVTV-1)
speciﬁc SFC7sem are shown.
Fig. 5. Memory B cells pre and post-challenge. (A) Env (HIVCZM gp120)- and
(B) Tat-speciﬁc IgG memory B cells, and (C) Env-Speciﬁc IgA memory B cells
2 weeks after the second protein immunization (wk 38) and 2 weeks post-
challenge (wk 52). Results are presented for fresh cells and for cells after 3 days of
stimulation as mean percent of total IgG or IgA ASC as appropriate,7sem.
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the Env of the SHIV1157ipd3N4 challenge virus, so the result might
reﬂect in part envelope variability. However, an anamnestic
response was not seen for Tat assayed using HIV clade B
consensus peptides, closely related to the HXB2 Tat component
of the challenge virus. Thus, although memory T cells were
elicited by the vaccine regimen, no recall in cellular response to
the challenge exposure was observed.
As the protection elicited by the previous Tat/Env vaccine
regimen was associated with humoral immunity (Florese et al.,
2009), we next assessed memory B cells in bone marrow of the
immunized macaques. Env-and Tat-speciﬁc IgG memory B cells
were most evident in the Tat/Env group in fresh cells assayed
2 weeks after the second protein boost (wk 38; Fig. 5A and B).
Two weeks post-challenge (wk 52) Env-Speciﬁc antibody secreting
cells (ASC) also appeared in the Env group. After 3 days of
stimulation, both Env and Tat-speciﬁc ASC were observed in their
respective immunization groups. A clear anamnestic response at
2 weeks post-challenge (wk 52) in Env-speciﬁc ASC was seen in
both the stimulated Env and Tat/Env groups (Fig. 5A), but such a
response for Tat was lacking (Fig. 5B). Env-speciﬁc IgA memory B
cells were also observed, with anamnestic responses exhibited in
both the Env and Tat/Env groups (Fig. 5C).
Post-challenge humoral immune responses
As memory B cells were recalled after the SHIV1157ipd3N4
exposure, we next investigated several anti-Env responsespre- and post-challenge. Anti-Env binding antibodies in serum
exhibited an anamnestic response in both the Env and Tat/Env
groups, with similar increases in titer by 4 weeks post-challenge
(Fig. 6A). Serum anti-Tat binding antibodies were not assessed.
Anamnestic antibody responses were also observed in rectal
secretions for Env-speciﬁc IgG responses in both the Env and
Fig. 6. Post-challenge humoral immune responses. (A) Env (HIVCZM gp120)-speciﬁc binding antibody. (B) Env- and (C) Tat-speciﬁc IgG antibody in rectal secretions.
(D) Neutralization of SHIV1157ipdEL-p. Geometric mean titers are plotted.
Fig. 7. Comparison of humoral immune responses between the ﬁrst and second Tat/Env studies. (A) Serum binding antibody titer in the Tat/Env groups of the ﬁrst and
second studies. (B) ADCC titer and (C) % target cell killing in the Tat/Env groups of the ﬁrst and second studies. Data for the ﬁrst Tat/Env study were taken from Demberg
et al., 2007.
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Tat and Tat/Env groups (Fig. 6C).
Post-challenge neutralization titers were assessed against
HIVTV1.21, SHIV1157ipd3N4 and the tier 1 virus, SHIV1157ipEL-p
(Siddappa et al., 2010), on TZM-bl cells. Signiﬁcant neutralizing
titers developed only against SHIV1157ipEL-p (Fig. 6D), while titers
against the other two viruses remained below 50 or at control
levels. Both the Env and Tat/Env groups exhibited a more rapid
appearance of neutralizing antibody compared to either the Tat or
control groups as expected.
Comparative antibody responses between the two Tat/Env protocols
A direct comparison between antibody responses in the Tat/
Env groups of the previous and current protocol revealed sig-
niﬁcant differences. Macaques in the ﬁrst study exhibited a
more rapid anamnestic binding antibody response compared to
macaques in the second study (Fig. 7A). Prior to challenge, thegeometric mean antibody titers of the ﬁrst and second Tat/Env
groups were similar: 12 weeks prior to challenge the macaques of
the ﬁrst study exhibited titers only 1.6-fold higher than those of
the second, and at 2 (study 1) and 0 (study 2) weeks before
challenge, titers were only 2-fold higher in the ﬁrst Tat/Env group.
However, by week 2 post-challenge, macaques in the Tat/Env
group of the ﬁrst study exhibited a 6.6-fold increase in titer over
the pre-challenge level, whereas macaques in the second study
exhibited an increase of only 2.6-fold. At this time point, titers of
the ﬁrst study were signiﬁcantly elevated compared to titers of
the second study (geometric mean titers of 25,600 and 5603,
respectively, p¼0.0026).
The anamnestic ADCC response of the ﬁrst Tat/Env group was
also much more striking than that of the second, with titers rising
3 logs by 2 weeks and 4 logs by 4 weeks post-challenge (Fig. 7B).
In contrast, ADCC titers of the second Tat/Env group were only
marginally elevated. At the time of challenge, ADCC titers in the
two groups were similar (geometric mean titer of 100 for the ﬁrst
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challenge the Tat/Env group of the ﬁrst study had an ADCC titer of
20,20,490, while that of the second study was only 5179
(p¼0.0006). This result was mirrored by the level of ADCC killing.
The ﬁrst Tat/Env group exhibited signiﬁcantly higher percent
killing at the time of challenge compared to the second study
(p¼0.010) and also exhibited a clear anamnestic response, rising
to a percent killing of 40.7, whereas the response of the second
group remained ﬂat with only 19.3% killing (po0.0001; Fig. 7C).
The lack of a strong anamnestic ADCC response in the Tat/Env
group of the current study prompted us to consider differences in
antibody epitopes potentially associated with the activity.
We therefore conducted pepscan analysis for sera of the Tat/Env
group pre- (week 38) and post- (week 52) challenge against both
HIVTV-1 and SHIV1157ipd3N4 Env peptides, and compared the
results with pepscan analysis of the previous Tat/Env group
against SHIV89.6P Env peptides. The Tat/Env group of the current
study exhibited no or very low binding to SHIV1157ipd3N4 peptides
both pre-and post-challenge, with peak absorbance reaching no
more than 0.2 for any given peptide. Responses to HIVTV-1
peptides were somewhat higher, occasionally reaching an absor-
bance of 0.25. No signiﬁcant boosting was observed post-chal-
lenge, and no distinct pattern of reactivity was observed (data not
shown). In contrast, animals from the Tat/Env group of the
previous study (Demberg et al., 2007) showed strong and broad
responses to SHIV89.6p envelope peptides, both pre- and post-
challenge, often exceeding OD values of 1.0, and with peak
responses reaching OD levels of 3.0 to 4.0. Clear boosting of antibody
reactivities was observed post-challenge (data not shown).
To further evaluate the quality of the antibody response
induced, we evaluated avidity, comparing the serum binding
antibody of the Tat/Env groups of the ﬁrst and second studies at
week 38 post-immunization. The mean half-maximal binding
titers of sera from the ﬁrst study against SHIV89.6P envelope and
the second study against HIVCZM were 53937898 and 14057114,
respectively (p¼0.0003). The calculated avidity indices were mar-
ginally signiﬁcantly different: 69.474.7 for the ﬁrst study and
53.171.4 for the second study (p¼0.051).Discussion
Because Tat can stimulate production of Th1 cytokines and
chemokines through its uptake into monocyte derived dendritic
cells (MDDC; Caputo et al., 2009), we initially pursued the idea
that priming with Ad5hr-HIVtat might modulate responses to Env
in the Tat/Env group leading to enhanced immunity. We found,
however, that overall responses were to the Ad vector itself, and
the inserted genes had no additional impact. Responses in PBMC
were relatively low, and remained low after the second
Ad-immunizations (Fig. 1A–C), perhaps reﬂecting emergence of
anti-Ad cellular and humoral responses (Peng et al., 2005; Qureshi
et al., 2012). Responses in BAL were consistently higher even after
the ﬁrst Ad immunization, and were dramatically boosted by the
second Ad administration (Fig. 1D and E). Replication-competent
Ad in rhesus macaques is broadly distributed in macaque tissues,
regardless of immunization route, and targets and persists in
macrophages and mDC in BAL and rectal tissue (Patterson et al.,
2012), perhaps explaining the increased expression of all cyto-
kines/chemokines in BAL cells. Previous studies have addressed
short term induction of cytokines and chemokines over hours to a
few days after exposure to replication-defective Ad in humans
and mice (Hartman et al., 2008; Higginbotham et al., 2002;
Zsengeller et al., 2000). TNF-a, IL-6, MIP-2, and MIP-1a were
strongly induced following pulmonary exposure to human Ad5 in
the mouse model (Zsengeller et al., 2000), in agreement with ourTNF-a and MIP-1a results in BAL cells. Further, the induction of
MIP-1a in PBMC seen here is similar to that described for wild
type Ad5 in human PBMCs (Higginbotham et al., 2002).
We could not explain the altered challenge outcome by the
cellular immune responses, which were strongly induced. In some
cases CD4 responses to Tat and Env tended to be higher than CD8
responses, contrary to the notion that Ad vaccination targets
mainly CD8 cells (Asmuth et al., 2010; Ganguly et al., 2011;
Kaufman et al., 2008). CD8 responses may have been under-
estimated due to induction of a4b7 expression as observed
previously by us (Zhou et al., 2007) and others (Ganguly et al.,
2011; Kaufman et al., 2008), and presumed migration of the CD8 T
cells to mucosal sites. Such gut homing of Ad-induced CD4 T cells
occurs much less frequently (Sun et al., 2010).
Memory T cells in PBMC showed trends toward elevated Env
responses and greater polyfunctionality in the Tat/Env group
compared to the Env-only group, most evident for CD4þ EM T
cells. This was a promising result, as EM T-cell responses have
been associated with protection in the SIV model (Hansen et al.,
2011). Similarly, induction of B cell memory responses in bone
marrow tended to show elevated levels in the Tat/Env group by
the end of the vaccine regimen, although not statistically
signiﬁcant.
Considering the strong induction of cellular and humoral
immune responses, including memory T and B cells, we were
surprised to ﬁnd no protection against the clade C SHIV1157ipd3N4
challenge. Previously, although acute viremia was not reduced
following vaccination with either the Tat-only or Tat/Env regimen
(Demberg et al., 2007; Fig. 3), the Tat/Env regimen had provided a
highly signiﬁcant 4 log reduction in chronic phase viremia,
correlated with binding antibody titers to Tat and Env (Florese
et al., 2009). Here, the Tat-only vaccine was similarly ineffective,
however, so were both the Env-only and the Tat/Env combined
vaccine regimens. The reasons for this unexpected outcome were
not immediately apparent. A recent study reports that Tat binds
to the HIV envelope, thereby facilitating virus entry into MDDC
via an integrin-mediated pathway (Monini et al., 2012). Anti-Tat
antibody can block this integrin-mediated uptake, suggesting that
both anti-Tat and anti-Envelope antibodies are needed for the
most efﬁcient blocking of HIV spread. Biologically active Tat is
readily taken up by MDDC, but oxidized Tat, which undergoes
conformational changes and multimerization (Fanales-Belasio
et al., 2009) is not, suggesting that oxidized inactive Tat might
not elicit antibodies able to block the integrin binding site.
We retrospectively assessed the biologic activity of the Tat
preparation used here for immunization, obtained from the same
source as in the previous study, and found it to be inactive and
unable to transactivate. Therefore, although anti-Tat antibodies
were elicited to similar titers as in the ﬁrst Tat/Env study, the lack
of protection in the Tat/Env group in the current study may be in
part attributable to failure to elicit Tat antibodies able to block
HIV entry via the integrin mediated pathway. Future comparative
studies characterizing Tat antibodies elicited in the two Tat/Env
studies could address this possibility.
The experimental design of the current study did not replicate
the previous successful study exactly, differing by the hetero-
logous challenge and use of alum for both Env and Tat protein
immunizations. We ﬁrst considered that the SHIV1157ipd3N4 chal-
lenge might have had a replication advantage compared to the
previous SHIV89.6P challenge, due to greater ﬁtness attributable to
its possession of two NF-kB sites per long terminal repeat (LTR)
(Song et al., 2006), whereas SHIV89.6P has only one. However, a
comparison of the control groups in the two studies showed that
the SHIV89.6P virus maintained greater chronic phase viremia
levels than the clade C SHIV1157ipd3N4’ suggesting that viral ﬁtness
was not a cause of the poor protective efﬁcacy. Nevertheless, the
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protection. Although the dual-tropic SHIV89.6P used in the ﬁrst
Tat/Env study can utilize CCR5 for entry into CCR5-transfected
cells, its preferential co-receptor for primary PBMC is CXCR4
(Zhang et al., 2000). Therefore, in vivo it targets and depletes
CD4þ naı¨ve T cells that express CXCR4 (Nishimura et al., 2004). In
contrast, R5 tropic viruses such as SHIV1157ipd3N4 target CD4
memory T cells that express CCR5 (Grossman et al., 2006). The
different outcomes for the two studies compared here might be
related to these differences in tropism. Whereas the SHIV89.6P
challenge of the ﬁrst Tat/Env study should have left the CD4þ
memory T cells intact, providing help for elicitation of effective
anamnestic responses, the R5 tropic SHIV1157ipd3N4 challenge
would have depleted CD4þ memory T cells, effectively precluding
vaccine-elicited memory responses. This possibility provides a
further argument for use of CCR5-tropic viruses for challenge of
non-human primates in pre-clinical studies, so that vaccine
candidates can be appropriately evaluated, and strategies to
surmount this problem can be developed.
Further, the heterologous challenge was apparently so dissim-
ilar that it did not elicit an anamnestic response, in contrast to the
ﬁrst study, where the homologous challenge exposure signiﬁ-
cantly boosted immunity. Speciﬁcally, a rapid, high-level ana-
mnestic ADCC response was observed. Subsequently, continued
viral expression helped sustain this elevated functional activity,
thus contributing to reduced chronic viremia. Here, lacking the
initial boost in immune response, the persistent heterologous
viremia was not able to maintain vaccine-elicited Env-speciﬁc
ADCC activity. The lack of cellular anamnestic response suggests
that SHIV1157ipd3N4 T cell epitopes differed signiﬁcantly from the
immunizing antigens.
A degree of breadth was elicited in humoral immunity by the
vaccine regimen, however, as anamnestic Env antibody responses
were exhibited by binding antibodies in both serum and rectal
secretions and in both Env and Tat-speciﬁc memory B cells.
Nevertheless, we found the quality of vaccine-induced anti-Env
antibodies was inferior in this study compared to the previous
one. The functional antibody responses induced here were low
titered. Neutralizing antibody to HIVTV-1, the immunizing strain,
never developed, although neutralizing antibody rapidly devel-
oped post-challenge against the tier 1 virus, SHIV1157ipdEL-p
(Siddappa et al., 2010) compared to slow development in the
control macaques. SHIV1157ipd3N4 is a difﬁcult to neutralize tier
2 virus (Song et al., 2006), but neutralizing activity against it did
not appear even post-challenge. In contrast, neutralizing antibody
against the SHIV89.6P challenge virus of the ﬁrst study appeared
soon after viral exposure. Moreover, in the previous study, the
potent chronic phase protection seen in the Tat/Env immuniza-
tion group was correlated with anti-Env binding antibody and
ADCC activity (Florese et al., 2009). Here, ADCC activity was
detectable, but of much lower titer compared to the previous
Tat/Env group (Fig. 7 B and C). Additionally, while anti-Env IgG
antibodies were detected in rectal secretions, rectal anti-Env IgA
antibodies were induced at lower levels and only sporadically. We
have reported a correlation of mucosal IgA antibodies with
protection and delayed acquisition (Xiao et al., 2012, 2010). Their
absence here may have contributed to the lack of protection
against the intrarectal challenge.
Additionally, the Env antibody responses elicited here were of
poorer quality compared to those of the previous study, as
assessed by pepscan and avidity measurements. In the pepscan
analysis, sera from the Tat/Env group did not strongly recognize
homologous Env peptides of the immunizing strain in contrast to
results of the earlier study. Moreover, in the previous study,
binding antibodies exhibited higher avidity than those of the
current study. Higher avidity has been associated with betterprotection (Xiao et al., 2012; Zhao et al., 2009) and is also directly
correlated with functional antibody responses (Xiao et al., 2010).
The low-titers and poor quality of antibody responses suggest the
adjuvant used may have been suboptimal.
The change to use of alum adjuvant was made in order to
correspond to an earlier Tat plus Env combination study in
cynomolgus macaques (Ferrantelli et al., 2011), and to match a
future Tat plus Env vaccine trial. Alum has long been used as an
adjuvant and promotes immune responses independently of toll-
like-receptor (TLR) mechanisms (De Gregorio et al., 2009). While
initially believed to function by a ‘‘depot effect’’, promoting slow
release of antigen, more recently it has been seen as an antigen
delivery system (Moreﬁeld et al., 2005). As described by De
Gregorio et al. (2009), alum promotes uptake of antigen by DCs
and induces proinﬂammatory reactions leading to DC maturation
and enhanced immune responses. In contrast, MPL-SE is a TLR-4
agonist (Ishii and Akira, 2007) that activates cells including DCs
that express TLR-4. We did not directly compare alum versus
MPL-SE in this study. However, studies in non-human primates
are moving away from alum adjuvants and efforts to develop
other, more potent adjuvants should continue.
Overall, our results suggest the need for a strong anamnestic
response in control of chronic viremia. In general, viral hetero-
geneity is viewed as an issue related to elicitation of sterilizing
immunity which can lead to prevention of HIV acquisition.
However, as seen here, HIV heterogeneity can impact not only
viral acquisition, but also can modulate the host’s ability to
respond and control subsequent viremia in the absence of
sterilizing immunity. Moreover, to achieve a potent anamnestic
response, vaccine strategies incorporating protein immunizations
require use of adjuvants able to elicit high-quality antibody,
characterized by strong memory incorporating functional anti-
body activities and high avidity.Material and methods
Animals, immunization and challenge, and sample collection
Twenty-eight Indian origin rhesus macaques were housed at
Advanced BioScience Laboratories, Inc. (ABL; Rockville, MD) and
maintained according to institutional animal use committee
guidelines and the NIH Guide for the Care and Use of Laboratory
Animals. All animals were negative for SIV, STLV-1, and SRV and
the Mamu-Bn08 and Bn17 MHC-class I haplotypes. They were not
pre-screened for Ad5 antibody, as previous studies have shown
little to no pre-exititng Ad5 antibody in this species. Four Mamu
An01 positive animals were evenly distributed among the groups.
The immunization schedule was identical to that of our previous
Tat/Env study (Demberg et al., 2007). Animals (7 per group) were
vaccinated on week 0 via the intranasal (IN) and week 12 via the
intratracheal (IT) route with replication-competent Ad type 5 host
range mutant (Ad5hr) recombinants encoding HIVIIIB Tat, HIVTV-1
gp160, or both Tat and Env (0.5109 pfu per recombinant). For
the Tat and Env only groups and the control group, empty
Ad5hrDE3 vector was added to make the total Ad dose 1109
pfu. At weeks 24 and 36 the appropriate groups were boosted
with 10 mg HIVIIIB Tat protein (ABL), 100 mg oligomeric HIVTV-1
gp140DV2 envelope (Novartis Vaccines and Diagnostics,
Cambridge, MA), or a combination of the Tat and Env proteins
formulated in Alum adjuvant. The ﬁrst boost was administered
subscapularly, and the second subcutaneously. The controls
received adjuvant only. Animals were challenged at week 50
intrarectally with a single high dose (25 AID50) of the tier 2 clade
C SHIV1157ipd3N4 (Song et al., 2006).
Table 1
Real-time PCR primers.
Target Forward primer 50 to 30 Reverse Primer 50 to 30 Amplicon size (bp) Accession No. Ref.
IFN-g GCAACAAAAAGAAACGGGATGAC CTGACTCCTTTTTCGCTTCC 148 NM_001032905 Demberg et al. (2011)
IL-15 GAAGCTGGCATTCATGTCTTCA ACATTCACCCAGTTGGCTTC 77 NM_001044731
TNF-a AGCCCATGTTGTAGCAAACC GCTGGTTATCTGTCAGCTCCA 104 DQ902483 Demberg et al. (2011)
CCL-3 (MIP-1a) CCTCCTGCTGCTTCAGCTAC CTCCTTACTGGGGTCAGCAC 146 AF457195 Demberg et al. (2011)
CCL-4 (MIP-1b) CTTCCTCGCAACTTTGTGGT GCTTGCTTCTTTTGGTTTGG 88 NM_002984 Demberg et al. (2011)
CCL-5 (RANTES) AGTGGCAAGTGCTCCAACC CGAACCCATTTCTTCTCTGG 86 DQ913730 Hofmann-Lehmann et al. (2002)
CXCL8 (IL-8) GAGTGGACCACACTGTGCCA AAACTTCTCCACAACCCTCTGC 108 NM_001032965 Hardstedt et al. (2005)
IL-10 AGAACCACGACCCAGACATC GGCCTTGCTCTTGTTTTCAC 119 DQ890063 Demberg et al. (2011)
18s GCCCGAAGCGTTTACTTTGA TCCATTATTCCTAGCTGCGGTATC 81 NR_003286 Medeiros et al. (2003)
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cally over the immunization course. PBMCs were obtained by
Ficoll-Paque PLUS gradient (GE Healthcare) separation, whereas
BAL ﬂuids were subjected to 35%/65% percoll (Sigma-Aldrich)
gradient centrifugation. Cells were counted and checked for
viability by trypan blue (Sigma-Aldrich) staining.
Cytokine/chemokine analyses by real time PCR
Primers were designed from human or rhesus reference
sequences of the speciﬁc cytokine. Speciﬁc primers (Table 1) were
selected using web based primer3 software (http://frodo.wi.mit.
edu/cgibin/primer3/primer3_www.cgi) and tested to be exon-
spanning using Blat search (http://genome.ucsc.edu/index.html)
to avoid amplicons from genomic DNA. Total RNA was isolated
using Qiagen RNeasy kits (Qiagen) in combination with Qiagen
Shredder columns. cDNA was synthesized using superscript III
kits (Invitrogen) or Qiagen QuantiTect Kits. The manufacturers’
protocols were followed with the following modiﬁcations: both
poly-dT and random hexamers were used with the superscript III
kit, and for both kits the reverse transcription step was extended
to 1 h at 42 1C. All incubations were done on an Eppendorf
Mastergradient cycler. cDNAs were frozen at 20 1C until further
use. Real-time PCRs were performed on an ABI7000 (Applied
Bioscience) PCR machine. The PCR reactions contained 25 ml of
the Invitrogen Platinum SYBR Greener qPCR SuperMix-UDG with
ROX, 1 ng of cDNA template, and 1 ml of 10 mM primer working
stocks. Amplicons were generated as follows: 50 1C for 2 min,
95 1C for 5 min, followed by 45 cycles of 94 1C for 30 s, 59 1C for
15 s and 72 1C for 30 s. All samples were run in triplicate. To verify
speciﬁc amplicon sizes, PCR products were mixed with loading
buffer (MTR, Maryland) and 20 ml were loaded onto Invitrogen 4%
48-well or 4% 12-well E-gels. 10 bp and 25 bp ladders (Invitrogen)
served as size markers.
Interferon-g (IFN-g) ELISpot
Nunc Maxisorb plates were coated overnight at 4 1C with
100 ml of the U-Cytech anti-monkey IFN-g antibody in DPBS (Life
Technologies, Carlsbad, CA), washed once on an automated plate
washer (Molecular Devices), and blocked overnight at 4 1C with
200 ml of DPBSþ2% BSA. PBMCs were adjusted to either 2106
or 1106 cells/ml in R-10 medium. After an overnight stimula-
tion at 37 1C with a single pool of 23 clade B Tat peptides (AIDS
Research and Reference Reagent Program, DAIDS, NIAID) or 214
HIVTV-1 Env peptides (ABL) at a ﬁnal concentration of 1 mg/ml for
each peptide, cells were plated into triplicate wells of the coated
and blocked plates at 2105 and 1105 cell/well. Concanavalin
A (5 mg/ml) and R10 medium or R10 plus DMSO (0.7% ﬁnal
concentration) served as positive and negative controls. After a
5 h incubation at 37 1C, cells were removed by ﬂicking the plates
and remaining cells were lysed with 200 ml of ice cold distilledwater for 15 min. Plates were washed twice and 100 ml of
DPBSþ1% BSA containing the detection antibody (U-Cytech) were
added. After a 1 h incubation at 37 1C the plates were washed
again and 50 ml of DPBSþ1% BSA containing the secondary anti-
body (U-Cytech) were added and the plates incubated as above.
After 2 ﬁnal washes, the plates were blotted dry and 30 ml of an
activation solution (Activator 1 and 2 at a 1:1 ratio; U-Cytech)
were added. The reaction was stopped by rinsing the plates with
distilled water. Results are reported as spot forming cells (SFC)/
million PBMC after subtraction of spots in negative control wells.
CFSE proliferation
PBMCs (5106) were washed, and resuspended in 4 ml of
pre-warmed DPBS containing 0.1% BSA in a 15 ml conical tube,
and labeled with 1.5 mM CFSE (Invitrogen, Carlsbad, CA). The cells
were gently vortexed, incubated for 15 min at 37 1C, and the
staining reaction was quenched by adding 10 ml of cold (4 1C) R10
medium and incubating on ice for 8 min. The cells were pelleted
by centrifugation (350xg, 10 min at RT), washed once with 14 ml
of R10 medium, and resuspended in 4 ml of medium. One ml of
cell suspension was plated into wells of a 24-well plate. Cells
were stimulated with either HIVIIIB Tat protein (5 mg/ml), HIVTV-1
Env gp120 (5 mg/ml) or both according to immunization group.
Cells in R10 or stimulated with ConA (5 mg/ml) served as negative
and positive controls, respectively. On day 6 post-stimulation
cells were transferred into FACS tubes, washed once with PBS, and
stained for 25 min in the dark at RT with the following antibodies:
CD3 PE (clone SP34-2), CD8 PE-Cy7 (clone RPA-T8) and CD4 APC
(clone L200) (all from BD Biosciences). Subsequently, the cells
were washed in PBS and ﬁxed in 2% formaldehyde (Tousimis) in
PBS. Proliferation was evaluated by acquiring 100,000 cells in the
lymphocytic gate on a BD FACSCalibur and is expressed as the
percentage of cells which diluted out CFSE after subtraction of
background proliferation in unstimulated controls.
Multiparameter ﬂow cytometry
The antibody panel for ﬂow cytometry analysis consisted of
the following mouse or rat anti-human antibodies: CD3 Alexa
Fluor 700 (Clone SP34-2), CD4 PE-TR (clone L200, custom con-
jugated), CD95 PE-Cy5 (clone DX2), IFN-g APC (clone B27), IL-2
APC-Cy7 (clone MQ1-17H12, custom conjugated) (all from BD
Bioscience); CD8 Qdot 655 (Clone 3B5, custom conjugated;
Invitrogen); CD28 PE-Cy7 (Clone CD28.2; eBioscience, San Diego,
CA), TNFa PerCP-Cy5.5 (Clone Mab11; Biolegend, San Diego, CA),
and CCR7 FITC (clone 150503, R&D Systems, Minneapolis, MN).
Aqua (Invitrogen) was used for exclusion of dead cells. Each
antibody was titrated separately, and optimized amounts were
used. One million cells in 400 ml of R10 medium were stimulated
in FACS tubes for six hours with 1 mg/ml of either HIVIIIB Tat or
HIVTV1-Env gp120 peptides in the presence of 0.4 ml Golgi Plug
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9F10, eBioscience), and 3 ml anti-CD28-PE-Cy7. BAL cells were
stimulated with Tat and/or Env peptides according to immuniza-
tion group except at the week 38 time point where cells from all
animal groups were stimulated with both Tat and Env peptides.
Unstimulated and SEB-stimulated samples were used as negative
and positive controls, respectively. After stimulation, cells were
washed twice with 1x DPBS, re-suspended in 95 ml of 1xPBS, and
incubated at room temperature for 10 min with 5 ml of Aqua dye
stock (1:40 dilution). After two washes with DPBS, the cells were
incubated with CD4, CD8 and CD95 antibodies for 20 min at room
temperature in 100 ml of FACS buffer (2% FBS in DPBS). After
another two washes with FACS buffer, cells were incubated in
250 ml of ﬁx/perm buffer (BD Bioscience) for 20 min at 4 1C. Cells
were thereafter washed twice with perm/wash buffer (BD
Bioscience), incubated with CD3, IFN-g, IL-2 and TNF-a antibodies
for 20 min at 4 1C, washed twice with perm/wash buffer, and re-
suspended in 3.7% formaldehyde solution for FACS analysis on an
LSRII ﬂow cytometer (BD Bioscience) equipped with blue, red and
UV lasers. The frequency of cytokine positive cells was deter-
mined using FlowJo version 8.8.6 (Tree star, Inc., Ashland, OR),
and formatted and analyzed using Pestle and Spice software,
respectively (both provided by Mario Roederer, VRC, NIAID, NIH).
Evaluation of binding antibodies
Serum binding antibodies speciﬁc for HIVIIIB Tat, HIVCZM
gp120, and HIVTV-1 gp140 were evaluated by ELISA as previously
described (Demberg et al., 2012). Antibody titer was deﬁned as
the reciprocal of the serum dilution at which the optical density
of the test serum was at least twice that of a negative rhesus
macaque serum diluted at 1:50.
Mucosal IgA and IgG titers were assessed in rectal secretions
collected using WECK-CEL sponges (Medtronic Ophthalmics, Jackson-
ville, FL, USA) pre-moistened with 50 ml DPBS. The sponges were
inserted into the rectum of the animals for 5 min and subsequently
frozen at 70 1C. After thawing, sponges were transferred to 5 mm
pore size centrifugal ﬁlter units (ultrafree-MC amicon, Millipore, USA)
and clipped. Elution buffer (250 ml of 1% Igepal CA-630, 10x Sigma-
FAST protease inhibitor cocktail in DPBS) was slowly added to each
sponge. The ﬁlter units were spun at 1000 g for 30 min at 4 1C. The
cartridge was discarded and 5 ml of each sample was transferred onto
a Roche Chemstrip (Roche, USA) to test for blood contamination.
Samples positive for blood were excluded from the analysis. An ELISA
was performed by coating 96-well Microlon 600 half-area plates
(Greiner Bio-one, USA) with either HIV Tat or HIVCZM gp120 protein in
carbonate-bicarbonate buffer (pH 9.6) (Sigma-Aldrich) over night at
4 1C. Plates were washed, blocked with a 1:10 dilution of BSA
blocking buffer (KPL, USA) and washed again. Samples were serially
diluted in the plates and incubated over night at 4 1C. After washing,
the plates were incubated with HRP-conjugated anti-monkey IgG or
IgA antibodies, washed and developed with TMB substrate (KPL),
stopped with sulfuric acid, and read at 450 nm on an ELISA plate
reader (Biotek Powerwave). Titers were deﬁned as the reciprocal
dilution of secretion at which the OD of the test sample was twice
that of a negative sample at a 1:5 dilution. Total IgG and IgA in the
secretions were determined as described previously (Xiao et al.,
2010). Final results were expressed as speciﬁc activity: Env- or Tat-
speciﬁc IgG or IgA titer divided by mg of total IgG or IgA in the sample.
ADCC
The ability of sera to mediate ADCC was assessed using the
RFADCC assay as previously described using human PBMC as
effectors and HIV clade C CZM gp120-coated CEM.NKr cells
as targets at an E:T ratio of 50:1 (Gomez-Roman et al., 2006).Ten-fold serial dilutions of sera starting at 1:10 were evaluated.
ADCC titer was deﬁned as the reciprocal of the serum dilution at
which percent killing was greater than the mean plus three
standard deviations of all negative control samples.
Neutralizing antibody
The ability of sera to neutralize HIVTV1.21 (a pseudovirus grown on
293T cells) and primary isolates SHIV1157ipd3N4 and SHIV1157ipEL-p
grown on PBMC, was tested on TZM-bl cells as described previously
(Monteﬁori, 2004). Results are expressed as ID50 values: the reciprocal
of the sample dilution at which relative luminescence units were
reduced 50% compared to virus control wells containing no macaque
serum.
Avidity
Avidity of serum antibody was evaluated against HIVCZM or
SHIV89.6P gp120 proteins as previously described (Xiao et al.,
2010). The avidity index was calculated as ratio of the NaSCN-
treated serum dilution giving half-maximal binding to the PBS-
treated serum dilution giving half-maximal binding, multiplied
by 100.
PEPSCAN
PEPSCAN analysis against 214 HIVTV-1 and 214 SHIV1157ipd3N4
envelope peptides was conducted by ELISA. Wells of Nunc
Maxisorb 96-well plates were coated overnight at 4 1C with
500 ng peptide/well in 100 ml of sodium bicarbonate buffer (pH
9.6) and blocked with 200 ml of Pierce SuperBlock blocking buffer
in PBS for 1 h at RT. Sera (100 ml of 1:50 dilutions) were added
and incubated for 1 h at 37 1C. After 5 washes with PBSþ0.05%
Tween 20, 100 ml of horseradish peroxidise labelled goat anti-
human IgG antibody (1:100,000 dilution) were added and plates
were incubated for 1 h at 37 1C. After intensive washing, 100ul of
K-Blue Aqueous TMB Substrate (Neogen) were added for 30 min
at RT. Color development was stopped with 2 N sulfuric acid and
plates were read at 450 nm on a Molecular Devices E-max plate
reader.
B-cell ELISpot
Total and envelope-speciﬁc IgG and IgA ASC in bone marrow
were assessed fresh and after 3-days stimulation with 1 mg/ml
CpG (ODN-2006) (Operon), 0.5 mg/ml recombinant-Human sCD40L
(Peprotech), and 50 ng/ml recombinant-Human IL-21 (Peprotech)
as previously described (Brocca-Cofano et al., 2011). Resultant
spots were counted using an automated ELISPOT reader (Axioplan
2 imaging; Zeiss, Munchen, Germany). Env-speciﬁc IgG or IgA ASC
are reported as percent of total IgG or IgA ASC.
Statistical analyses
Differences in binding and ADCC antibody titers, and avidity
indices and half maximal binding titers were evaluated using the
Wilcoxon rank sum test. Differences in ADCC % killing were
analyzed using repeated measures analysis of variance.Acknowledgments
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